Explore an available treatment option for patients with HER2+ metastatic breast cancer

Introduction

Unmet need in HER2+ MBC

Efficacy and safety data from HER2CLIMB

Dosing and administration

Patient cases

Q&A

Meet the Speaker

Erika Hamilton, MD

Erika Hamilton, MD

Director of the Breast and Gynecologic
Research Program
Sarah Cannon Research Institute

Tiffany A. Traina, MD

Tiffany A. Traina, MD

Vice Chair, Oncology Care
Section Head, Triple Negative Breast Cancer
Clinical Research Program
Associate Attending Physician
Associate Professor
Weil Cornell Medical College

Charles E. Geyer, Jr., MD, FACP

Charles E. Geyer, Jr., MD, FACP

Lois E. and Carl A. Davis Centennial Chair in Cancer Research
Houston Methodist Cancer Center

Program Objectives

gear

Identify the unmet need and challenges in human epidermal growth factor receptor 2- postive (HER2+) metastatic breast cancer (MBC)

arrow

Explore expert insights and responses to questions from community practice

flag

Review the key efficacy and safety data from HER2CLIMB trial

mountain

Review patient cases

SEA-20-OSV1039